BioPharma Credit PLC USD · LSE:BPCP
BioPharma Credit PLC USD — BioPharma Credit — H1 2026 Earnings Presentation
11 slides from BioPharma Credit PLC USD's earnings presentation, Sep 24, 2026
Slide 1: Debt Capital for the Life Sciences Industry
Debt Capital for the Life Sciences Industry COMPANY PRESENTATION – September 2026 For additional information please email: ir@bpcruk.com or visit BioPharma Credit PLC’s website at www.bpcruk.com
Slide 2: Disclaimer
Disclaimer This presentation of information relating to BioPharma Credit PLC (“BPCR”) is confidential and is intended solely for the information and exclusive use of the person to whom it has been provided. It is not to be reproduced, or transmitted, in whole or in part, to third parties. This prese
Slide 3: Experienced Investment Team
Experienced Investment Team Pharmakon Advisors, LP Pedro Gonzalez de Cosio Martin Friedman Pablo Legorreta Co-Founder, Principal and CEO Principal Co-Founder and Principal Co-founded Pharmakon in 2009 Joined Pharmakon in 2011 Co-Founded Pharmakon in 2009 after 17 years in structured after 18 ye
Slide 4: Financial Highlights as at June 2026
Financial Highlights as at 30 June 20261 Source: Pharmakon 1. Past performance is not an indication of future performance. 3
Slide 5: Recent Material Updates
Recent Material Updates 1 July 2026 – 8 From 1 July 2026 to 8 September 2026, BPCR sold 13.8 million of 2.50 per cent. senior September 2026 unsecured convertible notes due 2032 issued by Zenas BioPharma, at an average price of $132.50. 10 July 2026 On 10 July 2026, BPCR entered into a $45 million s
Slide 6: BPCR currently has ~$1bn invested across 20 transactions
BPCR currently has ~$1bn invested across 20 transactions1 ($ millions) BPCR Investment 2 BioPharma Funds Projected IRR 3 Share (%) Share ($) Total Outstanding Remaining Outstanding Balances + Cash to Maturity Invested Balance Tranches Commitment (As at 22 September 2026) Insmed $512.0 10.5% 43% $218
Slide 7: BPCR currently holds investments in six convertible debt positions
BPCR currently holds investments in six convertible debt positions1 ($ millions) Convertible Debt Details BioPharma Credit1 Company Details Issuance Total Convert Current Investment Original Inv. Outstanding Current Investment Coupon Maturity 1 1 % of Portfolio Market Cap Asset (Indication) Date Iss
Slide 8: $150m senior secured corporate loan
$150m senior secured corporate loan Kestra: Kestra is a commercial-stage wearable medical device and digital healthcare company focused on improving cardiovascular outcomes through diagnostic monitoring and therapeutic technologies Market Cap: $1.5bn as of 18 September 2026 Cash: $245m as of 3
Slide 9: CHF 250m senior secured corporate loan
CHF 250m senior secured corporate loan Idorsia: Switzerland-based biopharmaceutical company specialized in the discovery, development, and commercialization of innovative small molecules Market Cap: $1.6bn as of 18 September 2026 Cash: CHF 89m as of 30 June 2026 LTM Sales: CHF 173m as of 30
Slide 10: $500m senior secured corporate loan
$500m senior secured corporate loan Mineralys: Clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone Market Cap: $2.5b
Slide 11: $400m committed debt financing
$400m committed debt financing ARCHIMED: Investment firm focused exclusively on healthcare industries Esperion: Commercial-stage biopharmaceutical company. The company has developed and is commercializing oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular dise